Optimizing Short-Term Maximal Exercise Performance: The Superior Efficacy of a 6 mg/kg Caffeine Dose over 3 or 9 mg/kg in Young Female Team-Sports Athletes
- Publikationstyp:
- Zeitschriftenaufsatz
- Metadaten:
-
- Autoren
- Houda Bougrine
- Achraf Ammar
- Atef Salem
- Khaled Trabelsi
- Haitham Jahrami
- Hamdi Chtourou
- Nizar Souissi
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:001183061700001&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.3390/nu16050640
- eISSN
- 2072-6643
- Externe Identifier
- Clarivate Analytics Document Solution ID: KW7I9
- PubMed Identifier: 38474768
- Ausgabe der Veröffentlichung
- 5
- Zeitschrift
- NUTRIENTS
- Schlüsselwörter
- caffeine intake
- dosages
- mild consumers
- side effects
- female athletes
- team sports
- athletic performance
- Artikelnummer
- ARTN 640
- Datum der Veröffentlichung
- 2024
- Status
- Published
- Titel
- Optimizing Short-Term Maximal Exercise Performance: The Superior Efficacy of a 6 mg/kg Caffeine Dose over 3 or 9 mg/kg in Young Female Team-Sports Athletes
- Sub types
- Article
- Ausgabe der Zeitschrift
- 16
Datenquelle: Web of Science (Lite)
- Andere Metadatenquellen:
-
- Abstract
- <jats:p>Caffeine (CAF) is among the most extensively researched dietary supplements worldwide. However, little is known about the relationship between dosage and performance enhancement, particularly in female athletes. This study aimed to explore the effects of three different CAF dosages (3 mg·kg−1, 6 mg·kg−1, and 9 mg·kg−1) on high-intensity exercise and the prevalence of undesirable side effects related to these doses among female team-sports athletes. All participants (n = 16; age: 16.9 ± 0.6 y; height: 1.64 ± 0.1 m; BMI: 21.6 ± 1.5 kg·m−2) were mild CAF consumers. This study had a randomized, crossover, double-blind design in which each athlete performed four experimental sessions after ingesting either a placebo (PLAC), 3 mg·kg−1 CAF (CAF-3), 6 mg·kg−1 CAF (CAF-6), or 9 mg·kg−1 of CAF (CAF-9), with an in-between washout period of at least 72 h. In each experimental session, 60 min after ingesting the capsules, participants underwent a countermovement jumps test (CMJ), modified agility t-test (MATT), repeated sprint ability (RSA) test, and a rating of perceived exertion (RPE) and completed the CAF side effects questionnaire. Our findings revealed that in comparison to the PLAC condition, the MATT, RSAmean, and RSAbest performances were significantly greater only under the CAF-6 and CAF-9 conditions. Although the RPE scores remained unchanged, CMJ performance improved under all CAF conditions. All the performance outcomes were better for the CAF-6 and CAF-9 conditions than for the CAF-3 condition. Notably, no significant difference between the CAF-6 and CAF-9 conditions was observed for any of these parameters despite the highest incidence of side effects being noted for the CAF-9 condition. In summary, our findings highlight the recommendation for a moderate CAF dosage of 6 mg·kg−1 rather than 3 or 9 mg·kg−1 to enhance various aspects of short-term maximal performance in mild-CAF-consumer female team-sports athletes while mitigating the occurrence of adverse CAF side effects.</jats:p>
- Autoren
- Houda Bougrine
- Achraf Ammar
- Atef Salem
- Khaled Trabelsi
- Haitham Jahrami
- Hamdi Chtourou
- Nizar Souissi
- DOI
- 10.3390/nu16050640
- eISSN
- 2072-6643
- Ausgabe der Veröffentlichung
- 5
- Zeitschrift
- Nutrients
- Sprache
- en
- Online publication date
- 2024
- Paginierung
- 640 - 640
- Status
- Published online
- Herausgeber
- MDPI AG
- Herausgeber URL
- http://dx.doi.org/10.3390/nu16050640
- Datum der Datenerfassung
- 2024
- Titel
- Optimizing Short-Term Maximal Exercise Performance: The Superior Efficacy of a 6 mg/kg Caffeine Dose over 3 or 9 mg/kg in Young Female Team-Sports Athletes
- Ausgabe der Zeitschrift
- 16
Datenquelle: Crossref
- Abstract
- Caffeine (CAF) is among the most extensively researched dietary supplements worldwide. However, little is known about the relationship between dosage and performance enhancement, particularly in female athletes. This study aimed to explore the effects of three different CAF dosages (3 mg·kg<sup>-1</sup>, 6 mg·kg<sup>-1</sup>, and 9 mg·kg<sup>-1</sup>) on high-intensity exercise and the prevalence of undesirable side effects related to these doses among female team-sports athletes. All participants (n = 16; age: 16.9 ± 0.6 y; height: 1.64 ± 0.1 m; BMI: 21.6 ± 1.5 kg·m<sup>-2</sup>) were mild CAF consumers. This study had a randomized, crossover, double-blind design in which each athlete performed four experimental sessions after ingesting either a placebo (PLAC), 3 mg·kg<sup>-1</sup> CAF (CAF-3), 6 mg·kg<sup>-1</sup> CAF (CAF-6), or 9 mg·kg<sup>-1</sup> of CAF (CAF-9), with an in-between washout period of at least 72 h. In each experimental session, 60 min after ingesting the capsules, participants underwent a countermovement jumps test (CMJ), modified agility t-test (MATT), repeated sprint ability (RSA) test, and a rating of perceived exertion (RPE) and completed the CAF side effects questionnaire. Our findings revealed that in comparison to the PLAC condition, the MATT, RSA<sub>mean</sub>, and RSA<sub>best</sub> performances were significantly greater only under the CAF-6 and CAF-9 conditions. Although the RPE scores remained unchanged, CMJ performance improved under all CAF conditions. All the performance outcomes were better for the CAF-6 and CAF-9 conditions than for the CAF-3 condition. Notably, no significant difference between the CAF-6 and CAF-9 conditions was observed for any of these parameters despite the highest incidence of side effects being noted for the CAF-9 condition. In summary, our findings highlight the recommendation for a moderate CAF dosage of 6 mg·kg<sup>-1</sup> rather than 3 or 9 mg·kg<sup>-1</sup> to enhance various aspects of short-term maximal performance in mild-CAF-consumer female team-sports athletes while mitigating the occurrence of adverse CAF side effects.
- Addresses
- High Institute of Sport and Physical Education Gafsa, University of Gafsa, Gafsa 2100, Tunisia.
- Autoren
- Houda Bougrine
- Achraf Ammar
- Atef Salem
- Khaled Trabelsi
- Haitham Jahrami
- Hamdi Chtourou
- Nizar Souissi
- DOI
- 10.3390/nu16050640
- eISSN
- 2072-6643
- Externe Identifier
- PubMed Identifier: 38474768
- PubMed Central ID: PMC10935148
- Open access
- true
- ISSN
- 2072-6643
- Ausgabe der Veröffentlichung
- 5
- Zeitschrift
- Nutrients
- Schlüsselwörter
- Humans
- Caffeine
- Exercise
- Cross-Over Studies
- Double-Blind Method
- Adolescent
- Female
- Athletic Performance
- Athletes
- Team Sports
- Sprache
- eng
- Medium
- Electronic
- Online publication date
- 2024
- Open access status
- Open Access
- Paginierung
- 640
- Datum der Veröffentlichung
- 2024
- Status
- Published
- Publisher licence
- CC BY
- Datum der Datenerfassung
- 2024
- Titel
- Optimizing Short-Term Maximal Exercise Performance: The Superior Efficacy of a 6 mg/kg Caffeine Dose over 3 or 9 mg/kg in Young Female Team-Sports Athletes.
- Sub types
- research-article
- Randomized Controlled Trial
- Journal Article
- Ausgabe der Zeitschrift
- 16
Files
https://europepmc.org/articles/PMC10935148?pdf=render
Datenquelle: Europe PubMed Central
- Abstract
- Caffeine (CAF) is among the most extensively researched dietary supplements worldwide. However, little is known about the relationship between dosage and performance enhancement, particularly in female athletes. This study aimed to explore the effects of three different CAF dosages (3 mg·kg-1, 6 mg·kg-1, and 9 mg·kg-1) on high-intensity exercise and the prevalence of undesirable side effects related to these doses among female team-sports athletes. All participants (n = 16; age: 16.9 ± 0.6 y; height: 1.64 ± 0.1 m; BMI: 21.6 ± 1.5 kg·m-2) were mild CAF consumers. This study had a randomized, crossover, double-blind design in which each athlete performed four experimental sessions after ingesting either a placebo (PLAC), 3 mg·kg-1 CAF (CAF-3), 6 mg·kg-1 CAF (CAF-6), or 9 mg·kg-1 of CAF (CAF-9), with an in-between washout period of at least 72 h. In each experimental session, 60 min after ingesting the capsules, participants underwent a countermovement jumps test (CMJ), modified agility t-test (MATT), repeated sprint ability (RSA) test, and a rating of perceived exertion (RPE) and completed the CAF side effects questionnaire. Our findings revealed that in comparison to the PLAC condition, the MATT, RSAmean, and RSAbest performances were significantly greater only under the CAF-6 and CAF-9 conditions. Although the RPE scores remained unchanged, CMJ performance improved under all CAF conditions. All the performance outcomes were better for the CAF-6 and CAF-9 conditions than for the CAF-3 condition. Notably, no significant difference between the CAF-6 and CAF-9 conditions was observed for any of these parameters despite the highest incidence of side effects being noted for the CAF-9 condition. In summary, our findings highlight the recommendation for a moderate CAF dosage of 6 mg·kg-1 rather than 3 or 9 mg·kg-1 to enhance various aspects of short-term maximal performance in mild-CAF-consumer female team-sports athletes while mitigating the occurrence of adverse CAF side effects.
- Date of acceptance
- 2024
- Autoren
- Houda Bougrine
- Achraf Ammar
- Atef Salem
- Khaled Trabelsi
- Haitham Jahrami
- Hamdi Chtourou
- Nizar Souissi
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/38474768
- DOI
- 10.3390/nu16050640
- eISSN
- 2072-6643
- Externe Identifier
- PubMed Central ID: PMC10935148
- Ausgabe der Veröffentlichung
- 5
- Zeitschrift
- Nutrients
- Schlüsselwörter
- athletic performance
- caffeine intake
- dosages
- female athletes
- mild consumers
- side effects
- team sports
- Adolescent
- Female
- Humans
- Athletes
- Athletic Performance
- Caffeine
- Cross-Over Studies
- Double-Blind Method
- Exercise
- Team Sports
- Sprache
- eng
- Country
- Switzerland
- PII
- nu16050640
- Datum der Veröffentlichung
- 2024
- Status
- Published online
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2024
- Titel
- Optimizing Short-Term Maximal Exercise Performance: The Superior Efficacy of a 6 mg/kg Caffeine Dose over 3 or 9 mg/kg in Young Female Team-Sports Athletes.
- Sub types
- Randomized Controlled Trial
- Journal Article
- Ausgabe der Zeitschrift
- 16
Datenquelle: PubMed
- Author's licence
- CC-BY
- Autoren
- Houda Bougrine
- Achraf Ammar
- Atef Salem
- Khaled Trabelsi
- Haitham Jahrami
- Hamdi Chtourou
- Nizar Souissi
- Hosting institution
- Universitätsbibliothek Mainz
- Sammlungen
- DFG-491381577-G
- Resource version
- Published version
- DOI
- 10.3390/nu16050640
- File(s) embargoed
- false
- Open access
- true
- ISSN
- 2072-6643
- Ausgabe der Veröffentlichung
- 5
- Zeitschrift
- Nutrients
- Schlüsselwörter
- 796 Sport
- 796 Athletic and outdoor sports and games
- Sprache
- eng
- Open access status
- Open Access
- Paginierung
- 640
- Datum der Veröffentlichung
- 2024
- Public URL
- https://openscience.ub.uni-mainz.de/handle/20.500.12030/10276
- Herausgeber
- MDPI
- Datum der Datenerfassung
- 2024
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2024
- Zugang
- Public
- Titel
- Optimizing short-term maximal exercise performance : the superior efficacy of a 6 mg/kg caffeine dose over 3 or 9 mg/kg in young female team-sports athletes
- Ausgabe der Zeitschrift
- 16
Files
optimizing_shortterm_maximal_-20240402101601566.pdf
Datenquelle: OPENSCIENCE.UB
- Beziehungen:
- Eigentum von